CDKN1B and type 2 diabetes mellitus: The cyclin-dependent kinase inhibitor p27Kip1 is a major regulator of the podocyte hypertrophic response to hyperglycemia in vitro (85) and in vivo in a mouse type 2 diabetes model (86) and levels of p27Kip1 radically increase in experimental nephritis (87).